Serum <scp>YKL</scp>‐40 in psoriasis with and without arthritis; correlation with disease activity and high‐resolution power Doppler ultrasonographic joint findings

Ahmed, Samar Farouk; Attia, Enas A. S.; Saad, Abeer A.; Sharara, Manal A; Fawzy, Hazem Mohammed Abdelrahman; El-Nahrery, Eslam

doi:10.1111/jdv.12653

Cited by 24 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, that study did not evaluate the relationship between serum YKL-40 levels and the severity of arthritis symptoms. Another study evaluated serum levels of YKL-40 in 48 psoriatic patients, including 26 patients with joint involvement [ 20 ]. The authors performed the clinical assessment of the patients with additional tests: Composite Psoriatic Disease Activity Index, total joint score and high-resolution power Doppler ultrasound.…”

Section: Discussionmentioning

confidence: 99%

Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis

Salomon

Matusiak

Nowicka-Suszko

et al. 2018

pdia

View full text Add to dashboard Cite

IntroductionPsoriasis is an inflammatory disease of a complex pathogenesis and arthritis is one of its most common complications. The biological role of chitinase-3-like protein 1 remains unknown. It is suggested that this protein takes part in processes such as proliferation, inflammation and tissue remodelling.AimTo determine whether YKL-40 can be a useful biomarker in psoriatic arthritis.Material and methodsThe study was performed on 42 patients with psoriatic arthritis: 28 men and 14 women, aged from 24 to 71 years. All patients met the diagnostic criteria (CASPAR) for psoriatic arthritis. The severity of psoriatic arthritis was assessed using 28-joint Disease Activity Score with CRP. The assessment of skin lesions was performed by Psoriasis Area and Severity Index (PASI) and, additionally, the Body Surface Area (BSA) was calculated. Blood samples were taken to measure the serum concentration of YKL-40, as well as C-reactive protein, erythrocyte sedimentation rate, white blood cell count and neutrophil count.ResultsYKL-40 serum levels were significantly higher in patients with psoriatic arthritis, compared to the control group. Moreover, a significant positive correlation between the activity of psoriatic arthritis measured by DAS 28 and serum level of YKL-40 was found. There was a positive correlation between serum YKL-40 and BSA, as well as a distinct trend towards significance between YKL-40 and PASI score.ConclusionsYKL-40 can be a useful biomarker for both diagnosing and monitoring joint involvement in psoriatic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis

Salomon

Matusiak

Nowicka-Suszko

et al. 2018

pdia

View full text Add to dashboard Cite

show abstract

“…These changes are associated with differential circulatory and synovial expression of angiogenic factors, such as vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang2), placental growth factors (PIGF), and stromal derived growth factor-1 (SDF-1), in addition to cytokines and matrix metalloproteinases (MMPs) [1, 6–10]. Increased expression of these growth factors has been demonstrated in early PsA synovial membrane compared to RA [7, 9, 11], suggesting that mechanisms involved in regulating the distinct vascular morphology in PsA occur at an early stage of disease.…”

Section: Introductionmentioning

confidence: 99%

Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis

et al. 2019

View full text Add to dashboard Cite

IntroductionAngiogenesis is an early event in the pathogenesis of both psoriatic arthritis (PsA) and rheumatoid arthritis (RA); however, there are striking differences in blood vessel morphology and activation between the two arthropathies. The aim of this study was to assess if the PsA and RA joint microenvironments differentially regulate endothelial cell function.MethodsPsA and RA primary synovial fibroblasts (SFC) were isolated from synovial biopsies, grown to confluence, and supernatants harvested and termed ‘conditioned media’ (CM). Human umbilical vein endothelial cells (HUVEC) were cultured with PsA SFC or RA SFC-CM (20%). HUVEC tube formation, migration, and PBMC adhesion were assessed by matrigel tube formation, wound repair, and PBMC adhesion assays. HUVEC cell surface expression of ICAM, VCAM, and E-Selectin was assessed by flow cytometry. Transcriptome analysis of genes promoting angiogenesis was performed by real-time PCR. Finally, a MSD multiplex angiogenic assay was performed on PsA SFC and RA SFC supernatants.ResultsMacroscopic synovitis and vascularity were similar in PsA and RA patients; however, significant differences in vascular morphological pattern were recorded with tortuous, elongated vessels observed in PsA compared to straight regular branching vessels observed in RA. Transcriptome analysis showed strong upregulation of the pro-angiogenic signature in HUVEC primed with PsA SFC-CM compared to RA SFC-CM and basal control. In parallel, paired PsA SFC-CM significantly induced HUVEC tube formation compared to that of RA SFC-CM. Furthermore, PsA SFC-CM induced HUVEC migration was paralleled by a significant induction in VEGFA, PFKFB3, ICAM-1, and MMP3 mRNA expression. A significant increase in PBMC adhesion and cell surface expression of VCAM-1, ICAM-1, and E-Selectin expression was also demonstrated in PsA SFC-CM-primed HUVEC compared to RA SFC-CM. Finally, VEGF, TSLP, Flt-1, and Tie-2 expression was elevated in PsA SFC-CM compared to RA SFC-CM, with no significant difference in other pro-angiogenic mediators including MIP-3, bFGF, PIGF, and MCP-1.ConclusionPsA SFC and RA SFC secreted factors differentially regulate endothelial cell function, with soluble mediators in the PsA joint microenvironment inducing a more pro-angiogenic phenotype compared to the RA.

show abstract

“…Previous studies have supported that YKL-40 has a role in the pathogenesis of psoriasis manifested by its up-regulation in serum of psoriatic patients [9][10][11][12]. They concluded that, the increased YKL-40 may point out psoriatic patients with a higher level of systemic inflammation [13], and can be used as a new marker for evaluation of disease severity and progression in psoriasis [14].…”

Section: Discussionmentioning

confidence: 94%

Study of YKL-40 Expression in Chronic Plaque Psoriasis: Case Controlled Study

EL-Setiha

Amin

Mohammed

et al. 2021

JAMMR

View full text Add to dashboard Cite

Background: Psoriasis is a common inflammatory skin disorder. The typical cutaneous lesions are papules and plaques covered with silvery scales distributed mainly on extensor aspects of extremities. The course and progression of the disease are unpredictable and vary in each patient. YKL-40 is a new inflammatory biomarker which may be involved the pathogenesis of the disease. Objective: The aim of this study was to study YKL-40 expression in patients with psoriasis to evaluate its possible role in the pathogenesis of psoriasis. Patients and Methods: This study included 30 patients with chronic plaque psoriasis and 10 healthy individuals of matched age and sex served as a control group. Punch biopsies of four mm were taken from the skin of psoriatic patients as well as from corresponding sites of control subjects. All specimens were examined by both hematoxylin and eosin stain and anti-YKL-40 stain. Results: The intensity of YKL-40 expression was upregulated in both epidermis and dermis of psoriatic skin in comparison with normal skin of control subjects. YKL-40 expression in psoriatic skin showed significant positive correlation with Psoriasis Area and Severity Index (PASI) score. Conclusion: YKL-40 involved in the pathogenesis of psoriasis manifested by its up-regulation in skin of psoriatic patients group in comparison to control group.

show abstract

Serum YKL‐40 in psoriasis with and without arthritis; correlation with disease activity and high‐resolution power Doppler ultrasonographic joint findings

Cited by 24 publications

References 39 publications

Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis

Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis

Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis

Study of YKL-40 Expression in Chronic Plaque Psoriasis: Case Controlled Study

Contact Info

Product

Resources

About